- Home
- PCRX vs MUC Comparison
PCRX vs MUC Comparison
Compare PCRX & MUC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- MUC
- Stock Information
- Founded
- PCRX 2006
- MUC 1997
- Country
- PCRX United States
- MUC United States
- Employees
- PCRX N/A
- MUC N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- MUC Investment Bankers/Brokers/Service
- Sector
- PCRX Health Care
- MUC Finance
- Exchange
- PCRX Nasdaq
- MUC Nasdaq
- Market Cap
- PCRX 1.2B
- MUC 1.0B
- IPO Year
- PCRX 2011
- MUC N/A
- Fundamental
- Price
- PCRX $23.96
- MUC $10.74
- Analyst Decision
- PCRX Strong Buy
- MUC
- Analyst Count
- PCRX 6
- MUC 0
- Target Price
- PCRX $33.83
- MUC N/A
- AVG Volume (30 Days)
- PCRX 769.6K
- MUC 292.8K
- Earning Date
- PCRX 11-06-2025
- MUC 01-01-0001
- Dividend Yield
- PCRX N/A
- MUC 4.19%
- EPS Growth
- PCRX N/A
- MUC N/A
- EPS
- PCRX 0.47
- MUC N/A
- Revenue
- PCRX $716,791,000.00
- MUC N/A
- Revenue This Year
- PCRX $7.27
- MUC N/A
- Revenue Next Year
- PCRX $10.18
- MUC N/A
- P/E Ratio
- PCRX $50.52
- MUC N/A
- Revenue Growth
- PCRX 3.14
- MUC N/A
- 52 Week Low
- PCRX $16.29
- MUC $9.19
- 52 Week High
- PCRX $27.64
- MUC $11.30
- Technical
- Relative Strength Index (RSI)
- PCRX 56.14
- MUC 47.96
- Support Level
- PCRX $22.29
- MUC $10.61
- Resistance Level
- PCRX $24.95
- MUC $10.78
- Average True Range (ATR)
- PCRX 1.23
- MUC 0.07
- MACD
- PCRX 0.09
- MUC -0.01
- Stochastic Oscillator
- PCRX 78.19
- MUC 44.83
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About MUC Blackrock MuniHoldings California Quality Fund Inc.
BlackRock MuniHoldings California Quality Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide shareholders with current income exempt from U.S. federal income taxes and California personal income taxes. The fund mainly invests in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax) and California personal income taxes. Under normal market conditions, it invests a majority of its managed assets in investment-grade municipal obligations with remaining maturities of one year or more at the time of investment. It can also invest in below investment-grade securities, or directly in such securities or synthetically through the use of derivatives.